目的 探討重組人血管內(nèi)皮抑制素聯(lián)合托泊替康治療復(fù)發(fā)性卵巢癌的臨床療效。方法 選取2014年3月-2016年1月中國人民解放軍第273醫(yī)院收治的復(fù)發(fā)性卵巢癌患者72例，隨機分為對照組和治療組，每組各36例。對照組患者靜脈滴注注射用鹽酸托泊替康，1.2 mg/m²加入生理鹽水100 mL中，滴注30 min，連續(xù)用藥5 d。治療組在對照組治療基礎(chǔ)上靜脈滴注重組人血管內(nèi)皮抑素注射液，15 mg加入生理鹽水500 mL，靜脈滴注5 h，連續(xù)給藥14 d。每21天為1個療程，所有患者治療2個療程。觀察兩組的臨床療效，同時比較兩組患者生活質(zhì)量和毒副反應(yīng)發(fā)生情況。結(jié)果 治療后，對照組總有效率30.56%，臨床受益率為58.34%，治療組總有效率為47.22%，臨床受益率為77.78%，兩組總有效率和臨床收益率比較差異均具有統(tǒng)計學意義（P<0.05）。對照組和治療組的生活質(zhì)量改善率分別為36.11%、52.78%，兩組比較差異有統(tǒng)計學意義（P<0.05）。與對照組比較，治療組患者白細胞減少、貧血、血小板減少、惡心嘔吐的發(fā)生率顯著降低，兩組比較差異有統(tǒng)計學意義（P<0.05），兩組肝功能異常發(fā)生率比較差異無統(tǒng)計學意義。結(jié)論 重組人血管內(nèi)皮抑素聯(lián)合托泊替康治療復(fù)發(fā)性卵巢癌具有較好的臨床療效，可以改善患者的生活質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of recombinant human endostatin combined with topotecan in treatment of recurrent ovarian cancer. Methods Patients (72 cases) with recurrent ovarian cancer in 273th Hospital of the Chinese People's Liberation Army from March 2014 to January 2016 were randomly divided into control and treatment groups, and each group had 36 cases. The patients in the control group were iv administered with Topotecan Hydrochloride for injection, 1.2 mg/m² added into normal saline 100 mL, and dripped in 30 min for 5 d. The patients in the treatment group were iv administered with Recombinant Human Endostatin Injection on the basis of the control group, 15 mg added into normal saline 500 mL, and dripped in 5 h for 14 d. Every 21 d was as a course of treatment, and the patients in two groups were treated for two courses. After treatment, the clinical efficacies were evaluated, and the life quality and adverse reaction in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 30.56% and 47.22%, and the clinical benefit rates in two groups were 58.34% and 77.78%, respectively, and there were differences between two groups (P<0.05). The life quality improvement rates in the control and treatment groups were 36.11% and 52.78%, and there were differences between two groups (P<0.05). Compared with the control group, the incidences of leukopenia, nausea and vomiting, anemia, and thrombocytopenia in the treatment group were significantly reduced, and there were differences between two groups (P<0.05). The incidence of abnormal liver function was similar between two groups, and there were no statistical significance. Conclusion Recombinant human endostatin combined with topotecan has clinical curative effect in treatment of recurrent ovarian cancer, and can improve the life quality, which has a certain clinical application value.